首页> 外文OA文献 >Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer

【2h】

Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer

机译：紫杉醇与拉帕替尼或安慰剂作为HER2阴性或未知转移性乳腺癌的一线治疗的随机试验，雌激素受体，孕激素受体，人表皮生长因子受体2（HER2）和表皮生长因子受体的表达及拉帕替尼的获益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Finn, Richard S.; Press, Michael F.; Dering, Judy; Arbushites, Michael; Koehler, Maria; Oliva, Cristina; Williams, Lisa S.; Di Leo, Angelo;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. [J] . Finn RS, Press MF, Dering J Journal of Clinical Oncology . 2009,第24期

机译：在紫杉醇联合拉帕替尼或安慰剂作为HER2阴性或未知转移性乳腺癌的一线治疗的随机试验中，雌激素受体，孕激素受体，人表皮生长因子受体2（HER2）和表皮生长因子受体的表达和拉帕替尼的获益。
3. Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer-CALGB 40302 (Alliance) [J] . Burstein Harold J., Cirrincione Constance T., Barry William T., Journal of Clinical Oncology . 2014,第35期

机译：内分泌疗法对表皮生长因子受体和人表皮生长因子受体的抑制或不抑制：接受或不接受拉帕替尼的夫伐他汀的随机，双盲，安慰剂对照III期临床试验，用于绝经后激素受体阳性的晚期乳腺癌女性CALGB 40302（联盟）
4. Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer-CALGB 40302 (Alliance) [J] . Burstein Harold J., Cirrincione Constance T., Barry William T., Journal of Clinical Oncology . 2014,第35期

机译：内分泌疗法对表皮生长因子受体和人表皮生长因子受体的抑制或不抑制：接受或不接受拉帕替尼的夫伐他汀的随机，双盲，安慰剂对照III期临床试验，用于绝经后激素受体阳性的晚期乳腺癌女性CALGB 40302（联盟）
5. Effect of preoperative cancer treatment on epidermal growth factor receptor (EGFR) receptor expression level in ABY-029 guided sarcoma surgery [C] . Xiaochun Xu, Kimberley S Samkoe, Eric R. Henderson Society of Photo-Optical Instrumentation Engineers;Conference on Molecular-Guided Surgery: Molecules, Devices, and Applications . 2020

机译：术前癌症治疗对ABY-029导向肉瘤手术中表皮生长因子受体（EGFR）受体表达水平的影响
6. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
7. Estrogen Receptor Progesterone Receptor Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer [O] . Richard S. Finn, Michael F. Press, Judy Dering, -1

机译：紫杉醇与拉帕替尼或安慰剂作为HER2阴性或未知转移性乳腺癌的一线治疗的随机试验雌激素受体孕激素受体人表皮生长因子受体2（HER2）和表皮生长因子受体的表达及拉帕替尼的获益
8. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer [O] . Powles, Thomas, Huddart, Robert A, Elliott, Tony, 2017

机译：III期双盲，随机试验，比较了人表皮生长因子受体1/2阳性转移性膀胱癌患者在一线化疗后维持拉帕替尼与安慰剂的疗效

著录项

引文网络

相似文献

相关主题

期刊订阅